Literature DB >> 8342044

Corticosteroid-induced osteoporosis.

J D Adachi1, W G Bensen, A B Hodsman.   

Abstract

Corticosteroid-induced osteoporosis is a major problem faced by rheumatologists, with up to 50% of patients at increased risk for vertebral fractures. Our current understanding of the pathophysiology of corticosteroid-induced osteoporosis suggests two basic problems: a reduction in bone formation and an increase in bone resorption leading to an overall reduction in bone mass. Adequate calcium and vitamin D intake, calcitonin, hormone-replacement therapy, and thiazide diuretics are of benefit in preventing corticosteroid-induced bone loss. Other therapies such as the bisphosphonates, fluoride, and anabolic steroids should be considered when fractures occur or ongoing bone loss is evident. A review of the literature outlining the pathophysiology, clinical features, assessment, and treatment is presented.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342044     DOI: 10.1016/s0049-0172(05)80029-0

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  12 in total

1.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

Review 2.  Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.

Authors:  R Whittington; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

3.  Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.

Authors:  W F Lems; W G Jacobs; J W Bijlsma; A Croone; H C Haanen; H H Houben; M I Gerrits; H J van Rijn
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 4.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

6.  Rheumatoid arthritis patients with hip fracture: a nationwide study.

Authors:  Y-C Lin; Y-H Li; C-H Chang; C-C Hu; D W Chen; P-H Hsieh; M S Lee; S W-N Ueng; Y Chang
Journal:  Osteoporos Int       Date:  2014-11-20       Impact factor: 4.507

7.  Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

Authors:  F Falcini; S Trapani; M Ermini; M L Brandi
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

Review 8.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

9.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

10.  The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients.

Authors:  Cecilia P Chung; Anthony S Russell; Maria I Segami; César A Ugarte
Journal:  Rheumatol Int       Date:  2003-11-20       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.